Brazil's Actions and Reactions in the Fight Against COVID-19 from January to March 2020.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
11 01 2021
Historique:
received: 28 10 2020
revised: 25 12 2020
accepted: 05 01 2021
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 20 1 2021
Statut: epublish

Résumé

The outbreak of the novel coronavirus SARS-CoV-2 and the disease it causes, COVID-19, which emerged in 2019, was identified by the World Health Organization as a public health emergency of international concern. Brazil actively responded to contain the virus. This case study aims to examine Brazil's response to COVID-19 by investigating the country's actions and reflecting upon the outcomes throughout January and March 2020. The data collection strategy included gathering data from the country's intergovernmental organization's official website, epidemiological bulletins, and news reports, guided by intersectoral and interdisciplinary themes. Although the highest incidence rates were in the most rich and populated region in Brazil, it was the poorest region that had the highest case fatality rate. Nevertheless, Brazil took several non-pharmaceutical measures to control and mitigate the spread of the virus. However, the strategy seems to have failed to consider regional and social inequalities. The actions of the health minister were undermined by a conflicting discourse between the minister and the president. The outbreak of COVID-19 added an extra burden on the country's healthcare system and the existing economic crises; exacerbated the inherent social, political, and economic challenges; and exposed the country's contradictions.

Identifiants

pubmed: 33440812
pii: ijerph18020555
doi: 10.3390/ijerph18020555
pmc: PMC7828043
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Cien Saude Colet. 2017 Apr;22(4):1055-1064
pubmed: 28444033
Cad Saude Publica. 2020 Apr 22;36(4):e00040620
pubmed: 32321072
Lancet. 2016 Apr 16;387(10028):1603-4
pubmed: 27116057
Lancet Public Health. 2020 May;5(5):e236-e237
pubmed: 32220654
Lancet Glob Health. 2019 Nov;7(11):e1575-e1583
pubmed: 31607469
Lancet. 2019 Jul 27;394(10195):345-356
pubmed: 31303318
J Crit Care. 2020 Jun;57:279-283
pubmed: 32173110
Cad Saude Publica. 2020 Apr 06;36(4):e00055520
pubmed: 32267384
Lancet. 2011 May 21;377(9779):1722-3
pubmed: 21561654
Rev Soc Bras Med Trop. 2020 Apr 06;53:e20200155
pubmed: 32267301

Auteurs

Ana Szylovec (A)

Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland.

Isis Umbelino-Walker (I)

Athena Institute, Faculty of Science, VU University Amsterdam, 1081 HV Amsterdam, The Netherlands.

Brittany Nicole Cain (BN)

Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland.

Hoi Tung Ng (HT)

Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland.

Antoine Flahault (A)

Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland.

Liudmila Rozanova (L)

Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH